4,6-二氯-3-甲基-1H-吡唑并[3,4-d]嘧啶 | 1211522-68-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 4,6-二氯-3-甲基-1H-吡唑并[3,4-d]嘧啶
• 中文别名: 4,6-二氯-3-甲基-1H-吡唑并[3,4-D]嘧啶
• 英文名称: 4,6-dichloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 4,6-dichloro-3-methyl-2H-pyrazolo[3,4-d]pyrimidine
• CAS: 1211522-68-7
• 化学式: C₆H₄Cl₂N₄
• 分子量: 203.031
• InChiKey: WAVYWHRLGFPXMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4,6-Dichloro-3-methyl-1h-pyrazolo[3,4-d]pyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,6-Dichloro-3-methyl-1h-pyrazolo[3,4-d]pyrimidine
CAS number: 1211522-68-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4Cl2N4
Molecular weight: 203.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,6-二氯-3-甲基-1H-吡唑并[3,4-d]嘧啶 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 caesium carbonate 、 对甲苯磺酸 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 41.0h， 生成 N-((1s,4s)-4-((3-methyl-6-((4-(piperidin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)cyclohexyl)acrylamide
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶衍生物作为不可逆的布鲁顿酪氨酸激酶抑制剂

  摘要：

  4,6-二取代的吡唑并[3,4- d ]嘧啶衍生物被探索为不可逆的布鲁顿酪氨酸激酶 (BTK) 抑制剂。基于对 BTK 酶和 TMD8 细胞的活性，用合成的 20 多种衍生物建立了构效关系，以确定初始命中化合物。结果表明，在吡唑并嘧啶的 C4 位引入 1-丙烯酰胺基-4-氨基哌啶 ( 1b )，如5e和 3-丙烯酰胺基苯胺 ( 1j ) 作为 4-位取代基，如9d、10d和10e，体外递送强效酶活性以及基于 TMD8 细胞的细胞毒性。考虑到激酶选择性谱，5e被选择用于使用 TMD8 细胞的鼠异种移植模型进行体内功效研究，其中5e表现出中等的肿瘤生长抑制活性。5e和9d的进一步优化可能会导致临床上有用的化合物来克服 B 细胞介导的血液癌症。

  DOI：

  10.1002/bkcs.12490
• 作为产物：
  描述：

  3-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diol 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 13.0h， 以25%的产率得到4,6-二氯-3-甲基-1H-吡唑并[3,4-d]嘧啶
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶衍生物作为不可逆的布鲁顿酪氨酸激酶抑制剂

  摘要：

  4,6-二取代的吡唑并[3,4- d ]嘧啶衍生物被探索为不可逆的布鲁顿酪氨酸激酶 (BTK) 抑制剂。基于对 BTK 酶和 TMD8 细胞的活性，用合成的 20 多种衍生物建立了构效关系，以确定初始命中化合物。结果表明，在吡唑并嘧啶的 C4 位引入 1-丙烯酰胺基-4-氨基哌啶 ( 1b )，如5e和 3-丙烯酰胺基苯胺 ( 1j ) 作为 4-位取代基，如9d、10d和10e，体外递送强效酶活性以及基于 TMD8 细胞的细胞毒性。考虑到激酶选择性谱，5e被选择用于使用 TMD8 细胞的鼠异种移植模型进行体内功效研究，其中5e表现出中等的肿瘤生长抑制活性。5e和9d的进一步优化可能会导致临床上有用的化合物来克服 B 细胞介导的血液癌症。

  DOI：

  10.1002/bkcs.12490

文献信息

• [EN] COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH<br/>[FR] COMPOSÉS MODULANT L'ACTIVITÉ DES RÉCEPTEURS EGFR ET MÉTHODES POUR TRAITER OU PRÉVENIR DES TROUBLES À L'AIDE DE CEUX-CI
  申请人：GATEKEEPER PHARMACEUTICALS INC

  公开号：WO2011140338A1

  公开（公告）日：2011-11-10

  Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.

  提供了用于治疗或预防激酶介导的疾病的化合物和方法。
• 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR20180137057A

  公开（公告）日：2018-12-27

  본 발명은 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.

  This is the translated text in Chinese: 本发明涉及连接嘧啶衍生物，其制备方法以及包含其作为有效成分的布鲁替罗辛酪氨酸激酶活性相关疾病的预防或治疗药物组合物。根据本发明，连接嘧啶衍生物具有优越的抑制布鲁替罗辛酪氨酸激酶或TMD80活性的能力，因此可以用于预防或治疗与布鲁替罗辛酪氨酸激酶活性相关的疾病，特别是癌症或自身免疫性疾病。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015113452A1

  公开（公告）日：2015-08-06

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本发明涉及抑制LRRK2激酶活性的新化合物，其制备方法，含有它们的组合物，以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways
  作者：Sarah Wagner-Griffin、Masahito Abe、Raphael I. Benhamou、Alicia J. Angelbello、Kamalakannan Vishnu、Jonathan L. Chen、Jessica L. Childs-Disney、Matthew D. Disney

  DOI：10.1021/acs.jmedchem.1c00414

  日期：2021.6.24

  Myotonic dystrophy type 2 (DM2) is one of >40 microsatellite disorders caused by RNA repeat expansions. The DM2 repeat expansion, r(CCUG)exp (where “exp” denotes expanded repeating nucleotides), is harbored in intron 1 of the CCHC-type zinc finger nucleic acid binding protein (CNBP). The expanded RNA repeat causes disease by a gain-of-function mechanism, sequestering various RNA-binding proteins including

  2 型强直性肌营养不良 (DM2) 是由 RNA 重复扩增引起的 >40 种微卫星疾病之一。DM2 重复扩增 r(CCUG) exp（其中“exp”表示扩增的重复核苷酸）包含在 CCHC 型锌指核酸结合蛋白 (CNBP) 的内含子 1 中。扩展的 RNA 重复通过功能获得机制引起疾病，隔离各种 RNA 结合蛋白，包括前 mRNA 剪接调节因子 MBNL1。MBNL1 的隔离导致其功能丧失和随之而来的天然底物选择性剪接的失调。值得注意的是，该 r(CCUG) exp导致成熟 CNBP mRNA 中内含子 1 的保留。在此，我们报告了与 r(CCUG) exp采用的结构结合的药物样小分子并改善 DM2 相关缺陷。这些小分子通过筛选来自以 RNA 为重点的小分子文库的命中进行优化，以提供一种化合物，该化合物可特异性结合 r(CCUG) exp并具有纳摩尔亲和力，促进其所在的异常保留内含子的内源性降解，并拯救选择性剪接缺陷。
• [EN] IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE<br/>[FR] INHIBITEURS DE LA KINASE ALK2 CONTENANT DE L'IMIDAZOLE
  申请人：BIOCRYST PHARM INC

  公开号：WO2018232094A1

  公开（公告）日：2018-12-20

  Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I), (II), (III), or (IV), or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

  揭示了化合物的公式（I）、（II）、（III）和（IV），以及它们的药用盐。这些化合物是ALK2激酶的抑制剂。还提供了包含公式（I）、（II）、（III）或（IV）的化合物或其药用盐的药物组合物，以及涉及使用这些化合物或其药用盐和组合物治疗和预防各种疾病和病况的方法，如纤维性骨化进行性疾病。